Holen Sie sich die Stockscreener-App
112.69
1.93%
2.13
Handel nachbörslich:
112.85
0.16
+0.14%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$110.56
Offen:
$110.74
24-Stunden-Volumen:
8.09M
Relative Volume:
1.28
Marktkapitalisierung:
$139.83B
Einnahmen:
$28.80B
Nettoeinkommen (Verlust:
$6.31B
KGV:
22.42
EPS:
5.0273
Netto-Cashflow:
$9.37B
1W Leistung:
+0.53%
1M Leistung:
-0.27%
6M Leistung:
+0.27%
1J Leistung:
+33.88%
1-Tages-Spanne:
$109.66
$113.59
1-Wochen-Bereich:
$108.46
$114.86
52-Wochen-Spanne:
$83.98
$121.83
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
112.69 | 137.18B | 28.80B | 6.31B | 9.37B | 5.0273 |
|
LLY
Lilly Eli Co
|
839.87 | 734.96B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
188.64 | 447.90B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
233.91 | 417.90B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
132.39 | 253.54B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
89.19 | 223.58B | 63.43B | 16.42B | 14.72B | 6.4861 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences (GILD) Laps the Stock Market: Here's Why - sharewise.com
RBC Capital Maintains a Hold Rating on Gilead Sciences (GILD) - Insider Monkey
Gilead Foundation Commits Over $6.5M in New Grant Funding to Support STEM Education Pathways - Yahoo Finance
How Gilead Sciences Inc. (Common Stock) (GIS0) stock responds to bond marketMarket Sentiment Summary & High Conviction Buy Zone Picks - newser.com
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock recover faster than industry2025 Year in Review & Stock Portfolio Risk Control - newser.com
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo
Gilead’s Lost Decade Is Over. It’s Time to Buy the Stock. - Barron's
Gilead stock faces potential hit if Biktarvy is Trump’s price cut target - Investing.com
Potential Price Pressures for Gilead (GILD) Shares - GuruFocus
RBC on Gilead Sciences (GILD): 'Could Biktarvy Be The $137 Pill Trump Wants To Cut To $18' - StreetInsider
Marginal Zone Lymphoma Market Growth Projections 2024-2034: DelveInsight Analysis | Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma - The Globe and Mail
Immatics Appoints Venkat Ramanan as Chief Financial Officer - GlobeNewswire Inc.
Using flow based indicators on Gilead Sciences Inc.2025 Sector Review & Short-Term High Return Strategies - newser.com
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock? - MSN
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
How to integrate Gilead Sciences Inc. into portfolio analysis toolsEarnings Miss & Weekly High Conviction Trade Ideas - newser.com
What Do Analysts Think About Gilead Sciences (GILD)? - Insider Monkey
Gilead signs $34.5M deal for Hanmi/HHP’s I.V.-to-oral drug tech - BioWorld MedTech
Gilead Sciences Begins On New California Manufacturing Hub - Construction Equipment Guide
One Wealth Advisors LLC Has $1.02 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Earnings visualization tools for Gilead Sciences Inc.2025 Risk Factors & Expert Approved Trade Ideas - newser.com
Capital Investment Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Raleigh Capital Management Inc. Sells 6,315 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
GC Wealth Management RIA LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Avior Wealth Management LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Hong Kong's Health Hope Pharma enters into virology deal with Gilead Sciences - BioSpectrum Asia
Will Gilead Sciences Inc. stock keep outperforming rivals2025 Top Decliners & Safe Capital Growth Trade Ideas - newser.com
Gilead pumps up virology pipeline with drug transporter deal - Fierce Biotech
What analyst consensus implies for Gilead Sciences Inc. (GIS) stockSell Signal & Smart Allocation Stock Tips - newser.com
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences - PR Newswire UK
Hanmi, HHP license oral drug delivery compound to Gilead By Investing.com - Investing.com Canada
Hanmi Pharmaceutical Signs Global Licensing Agreement with Gilead Sciences and Health Hope Pharma for Encequidar - Korea IT Times
Hanmi's Oral Delivery Platform Compound Licensed to Gilead - Eastern Progress
Real time scanner hits for Gilead Sciences Inc. explainedQuarterly Portfolio Summary & Reliable Intraday Trade Plans - newser.com
Hanmi's oral delivery platform compound licensed to Gilead - MarketScreener
Hanmi Pharm licenses oral drug delivery compound to Gilead Sciences - StreetInsider
Short interest data insights for Gilead Sciences Inc.2025 Investor Takeaways & Weekly Momentum Picks - newser.com
Gilead Sciences, Inc. $GILD Shares Sold by First County Bank CT - MarketBeat
Hanmi sells Encequidar oral absorption tech to Gilead in up to $34.5M dealCHOSUNBIZ - Chosun Biz
Will Gilead Sciences Inc. stock deliver strong dividend growth2025 Top Decliners & Weekly Return Optimization Plans - newser.com
Morgan Stanley Maintains Buy on Gilead Sciences (GILD) - Insider Monkey
Why Gilead Sciences Inc. (GIS) stock is a must watch tickerMarket Movement Recap & Free Weekly Watchlist of Top Performers - newser.com
Gilead Sciences, Inc. (NASDAQ:GILD) Is Favoured by Institutional Owners Who Hold 88% of the Company - 富途牛牛
Old Port Advisors Buys Shares of 7,321 Gilead Sciences, Inc. $GILD - MarketBeat
What analysts say about Gilead Sciences Inc GIS stockREITs Market Trends & Free Risk Assessment and Control - Early Times
Kathmere Capital Management LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
State of Alaska Department of Revenue Sells 6,285 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum - Yahoo Finance
How Gilead Sciences Inc. (Common Stock) (GIS0) stock moves in volatile trading sessions2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Is Gilead Sciences Inc. (GIS) stock included in top ETFsBuy Signal & Stock Portfolio Risk Management - newser.com
JPMorgan Lifts Gilead Sciences, Inc. (GILD)’s Price Target To $145, Maintains Overweight Rating - MSN
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.52%
0.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):